Cardiac AI’s Billion-Dollar De-Risking: The Reimbursement Blueprint

The vast, often opaque field of regulatory navigation and reimbursement acquisition in digital health has historically presented a formidable barrier for AI-driven innovators, particularly in high-stakes clinical domains like cardiology. Yet, for the discerning investor, this seemingly impenetrable thicket now reveals a clear, de-risked path, thanks to the pioneering efforts of a select few. The commercial success of early category-defining investments in coronary analysis has not merely validated the clinical promise of AI. It has fundamentally reshaped the market, establishing a replicable roadmap for scalable reimbursement that astute growth equity investors can use.

Charting the Course: How Cleerly and HeartFlow Forged the Reimbursement Pathway

The journey from novel AI algorithm to widely adopted, reimbursed clinical tool is arduous, often characterized by a “valley of death” where promising technologies languish without clear payment mechanisms. In cardiac AI, companies like Cleerly and HeartFlow stand as testament to the possibility of bridging this chasm. Their success wasn’t accidental. It was the result of a careful, multi-year strategy focused on securing regulatory clearances and, critically, dedicated reimbursement codes. HeartFlow, for instance, has been instrumental in establishing the viability of AI-driven fractional flow reserve (FFR) analysis from coronary computed tomography angiography (CTA) scans. This Software as a Medical Device (SaMD) offers a non-invasive alternative to traditional invasive FFR, aiding in the diagnosis of coronary artery disease. Their strategic engagement with the American Medical Association (AMA) led to the assignment of a specific Category I CPT code. For example, CPT code 75580, “Noninvasive estimated coronary fractional flow reserve (FFR) based on computed tomography angiography data, with anatomical analysis of coronary arteries, 3D rendering, and interpretation and report, including quantitative analysis of stenosis,” is a direct outcome of this effort. This Category I status signifies broad clinical acceptance and establishes a permanent reimbursement mechanism, a critical distinction from temporary Category III codes. The Medicare Physician Fee Schedule (MPFS) for 2025 assigns a national average payment rate of $1,017.39 for this code, providing financial predictability for providers adopting the technology. This de-risking of the commercial pathway makes adoption significantly more attractive for health systems and cardiologists alike. Similarly, Cleerly has navigated the complex regulatory field for its AI-driven quantitative coronary artery disease (CAD) analysis. Their approach focuses on characterizing plaque beyond simple stenosis, providing a more complete assessment of atherosclerosis. Cleerly’s innovations have also been recognized by the AMA, leading to the assignment of dedicated CPT codes that facilitate reimbursement. For example, CPT code 75577, “Quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, derived from augmentative software analysis of the data set from a coronary computed tomographic angiography, with interpretation and report by a physician or other qualified health care professional,” is a Category I CPT code, effective January 1, 2026. Medicare covers AI plaque analysis under CPT code 75577 at a payment rate of about $1,000 as of early 2026. Also, Cleerly’s ISCHEMIA software device can be billed using Category I CPT code 75580, effective January 1, 2024. The presence of such codes provides a vital framework for billing and collection, allowing early adopters to integrate the technology without bearing the full financial risk of an uncodified service AMA CPT code search.

The Blueprint for AI-Native Health Companies: Regulatory and Reimbursement Mapping

The success stories of HeartFlow and Cleerly offer a powerful blueprint for AI-native health companies seeking to scale within the cardiac AI sector and beyond. Their journey shows several critical components that investors should scrutinize when evaluating potential opportunities:

1. Early and Proactive Engagement with the AMA: Waiting until market penetration to seek CPT codes is a losing strategy. Both HeartFlow and Cleerly engaged with the AMA’s CPT Editorial Panel early in their commercialization cycles. This proactive approach ensures that the unique clinical value proposition of the AI is understood and appropriately categorized. For AI-native companies, especially those dealing with novel diagnostic or prognostic capabilities, this engagement is paramount. The AMA governs the reimbursement pathway for digital health technologies, and their buy-in is non-negotiable for broad adoption.

2. Strong Clinical Evidence for Efficacy and Utility: The AMA’s CPT Editorial Panel, as well as payers, demand rigorous clinical evidence demonstrating improved patient outcomes, clinical utility, and cost-effectiveness. This is where the “AI-native” definition truly comes into play: training on real patient outcomes data, operating within defined clinical guardrails, and publishing evidence of efficacy are not just good practice, but commercial imperatives. Companies that can demonstrate a data moat, built on proprietary, outcome-linked datasets, are inherently better positioned to generate this evidence. A strong QMS / ISO 13485 framework also underpins the credibility of this evidence.

3. Understanding the Nuances of CPT Category I vs. Category III: While Category I codes are the ultimate goal, Category III codes serve as an essential stepping stone. They allow for data collection on utilization and outcomes, which is important for demonstrating the value required for Category I conversion. Investors should assess a company’s strategy for progressing from Category III to Category I, including plans for post-market surveillance and real-world evidence (RWE) generation CPT Category III codes information.

4. Working through CMS and Payer Adoption: Securing a CPT code is a necessary, but not sufficient, condition for reimbursement. Companies must then secure coverage decisions from Medicare (CMS) and private payers. The established precedent set by HeartFlow and Cleerly in cardiac imaging AI significantly de-risks this second stage. Payers are more likely to cover a new technology when similar, AI-driven diagnostics have already proven their value and established a billing infrastructure. This is where understanding the Medicare Physician Fee Schedule (MPFS) and potential for New Technology Add-On Payments (NTAP) becomes critical for inpatient settings.

The Investor Takeaway: Identifying the Next Wave of De-Risked AI Innovators

For growth equity investors, the commercial achievements of HeartFlow and Cleerly are more than just individual success stories. They represent a fundamental de-risking of the entire cardiac AI sector. The path to scalable reimbursement, once nebulous, is now clearly delineated. Investors should actively seek out emerging AI-native health companies that are carefully following this established roadmap. Look for startups that:

• Possess a compelling wedge product in cardiac care, with clear plans for expansion into adjacent use cases.
• Are generating strong clinical evidence, ideally through large-scale, real-world data studies, to support their claims of efficacy and utility.
• Have a proactive strategy for AMA engagement and CPT code acquisition, with a clear understanding of the transition from Category III to Category I.
• Demonstrate a strong understanding of the reimbursement field, including potential Medicare and private payer coverage pathways.
• Exhibit a strong regulatory posture, with a clear 510(k) or De Novo pathway, and an understanding of GMLP principles to avoid regulatory debt.

The pioneering investments in coronary analysis have not just created value for their own stakeholders. They have built the foundational infrastructure for the next generation of cardiac AI innovation. By understanding and using this established blueprint, investors can confidently identify and back the AI-native health companies poised to capture significant market share and deliver substantial returns.

Methodology and Source Note: This analysis is based on publicly available data from the American Medical Association’s CPT code registry and the Centers for Medicare & Medicaid Services (CMS) Medicare Physician Fee Schedules. Specific CPT codes and reimbursement rates are subject to change based on annual updates and local carrier determinations.